Begin main content

Search

We found 606 result(s)

Denosumab (Drug Plan Submission) (Xgeva)

Last Updated: September 7, 2018
Result type: Reports
Product Line: Common Drug Review
Generic Name: Denosumab (Drug Plan Submission)
Indications: Prevention of skeletal-related events due to bone metastases from breast cancer

  • Brand Name: Xgeva
  • Manufacturer: Amgen Canada Inc.
  • Project Number: SR0433-000
  • Project Status: Complete
  • Submission Type: New

ticagrelor (Brilinta)

Last Updated: October 10, 2018
Result type: Reports
Product Line: Common Drug Review
Generic Name: ticagrelor
Indications: Prevention of atherothrombotic events with history of myocardial infarction

  • Brand Name: Brilinta
  • Manufacturer: AstraZeneca Canada Inc
  • Project Number: SR0474-000
  • Project Status: Complete
  • Submission Type: New Indication

Secukinumab (Cosentyx)

Last Updated: January 21, 2016
Result type: Reports
Product Line: Common Drug Review
Generic Name: Secukinumab
Indications: Arthritis, psoriatic

  • Brand Name: Cosentyx
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0476-000
  • Project Status: Complete
  • Submission Type: New

Sapropterin dihydrochloride (Kuvan)

Last Updated: January 4, 2016
Result type: Reports
Product Line: Common Drug Review
Generic Name: Sapropterin dihydrochloride
Indications: Phenylketonuria (PKU)

  • Brand Name: Kuvan
  • Manufacturer: BioMarin Pharmaceutical (Canada) Inc.
  • Project Number: SR0472-000
  • Project Status: Complete
  • Submission Type: Resubmission

dapagliflozin/metformin hydrochloride (XigDuo)

Last Updated: December 1, 2015
Result type: Reports
Product Line: Common Drug Review
Generic Name: dapagliflozin/metformin hydrochloride
Indications: Diabetes Mellitus, Type 2

  • Brand Name: XigDuo
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: SR0468-000
  • Project Status: Complete
  • Submission Type: New

infliximab (Renflexis)

Last Updated: November 5, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: infliximab
Indications: rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis

  • Brand Name: Renflexis
  • Manufacturer: Merck Canada Inc.
  • Project Number: SE0532-000
  • Project Status: Complete
  • Submission Type: New

reslizumab (Cinqair)

Last Updated: November 5, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: reslizumab
Indications: Asthma, eosinophilic

  • Brand Name: Cinqair
  • Manufacturer: TEVA Canada Innovation
  • Project Number: SF0591-000
  • Project Status: Complete
  • Submission Type: Request For Advice

Orilissa (elagolix) (Orilissa)

Last Updated: February 18, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: elagolix
Indications: Moderate to severe pain associated with endometriosis

  • Brand Name: Orilissa
  • Manufacturer: AbbVie Corporation
  • Project Status: Not filed
  • Submission Type: Non-submission

semaglutide (TBC )

Last Updated: October 24, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: semaglutide
Indications: diabetes mellitus, type 2

  • Brand Name: TBC
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0637-000
  • Project Status: Pending
  • Submission Type: New